BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 30511683)

  • 21. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.
    Yu S; Lin T; Nie D; Zhang Y; Sun Z; Zhang Q; Wang C; Xiong M; Fan Z; Huang F; Xu N; Liu H; Yu G; Zhang H; Shi P; Xu J; Xuan L; Guo Z; Wu M; Han L; Xiong Y; Sun J; Wang Y; Liu Q
    Blood Cancer J; 2021 Dec; 11(12):195. PubMed ID: 34873148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.
    Zhao XS; Liu YR; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Han W; Sun YQ; Yan CH; Mo XD; Wang YZ; Fan QZ; Wang XY; Liu KY; Huang XJ; Chang YJ
    Am J Hematol; 2019 May; 94(5):512-521. PubMed ID: 30680765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Canaani J; Labopin M; Huang XJ; Ciceri F; Van Lint MT; Bruno B; Santarone S; Diez-Martin JL; Blaise D; Chiusolo P; Wu D; Mohty M; Nagler A
    Br J Haematol; 2018 Nov; 183(3):411-420. PubMed ID: 30117144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
    Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
    Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
    Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
    Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
    J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Suo P; Zhang LP; Huang XJ
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e126-e136. PubMed ID: 33060049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
    Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet.
    Wang T; Chen S; Chen J; Liu T; Zhang T; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Transplant Cell Ther; 2021 Feb; 27(2):173.e1-173.e9. PubMed ID: 33830030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The comparison of predicting clinical outcomes between immunolophenotype and hematological complete remission before human leukocyte antigen-matched sibling donor transplantation in acute myeloid leukemia].
    Liu J; Liu YR; Wang YZ; Han W; Chen H; Chen Y; Wang JZ; Mo XD; Zhang YY; Yan CH; Sun YQ; Chen YY; Wang Y; Xu LP; Zhang XH; Liu KY; Huang XJ; Chang YJ
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):617-623. PubMed ID: 30180459
    [No Abstract]   [Full Text] [Related]  

  • 39. [The effect of WT1 expression on the prognosis of allogeneic hematopoietic stem cell transplantation in acute leukemia].
    Jiang BQ; Luo Y; Zhao YM; Tan YM; Yu J; Lai XY; Zhu YY; Sun J; Zheng WY; He JS; Wei GQ; Cai Z; Huang H; Shi JM
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):989-993. PubMed ID: 30612399
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
    Zhou W; Chen G; Gong D; Gao Y; Yu L
    Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.